From Targeted Science to Better Healthcare™
Clinical Data is a global biotechnology company developing early and late stage targeted therapeutics as well as genetic and pharmacogenomic tests that detect serious diseases and help predict drug safety, tolerability and efficacy. Our late-stage compounds include: Vilazodone, a potential first-in-class drug candidate for the treatment of depression, and Stedivaze™, a potential best-in-class cardiac stress agent. By employing biomarker strategies and technologies to develop targeted therapeutics with potential advantages over currently available treatments, thus, offering tangible benefits for patients, healthcare professionals and payers.

The Company’s PGxHealth division is further leveraging its biomarker discovery expertise and intellectual property to develop and commercialize pharmacogenomic tests to detect serious diseases and help predict drug safety, tolerability and efficacy. PGxHealth has built the commercial, managed care and CLIA-certified laboratory infrastructure and capabilities to support our currently marketed tests including the FAMILION® family of genetic tests for inherited heart diseases and PGxPredict™ tests for predicting drug response.

Featured Events:

Clinical Data, Inc, to Present at Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference
Aug 13, 2010 9:20 AM ET

Clinical Data, Inc, to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference
Aug 5, 2010 9:00 AM ET

Clinical Data, Inc, to Present at Wedbush Securities Life Sciences Best Ideas MAC Conference
Aug 3, 2010 3:00 PM ET

2010 BIO International Convention
McCormick Place, Chicago, Illinois
May 6, 2010, 2:00 - 3:30 PM CT

Clinical Data, Inc. to Host Investor Day and Webcast
October 8, 2009 8:30a ET
View Webcast
View Presentation